Teva says Optime Care can’t get out of US antitrust case over Korlym
MLex Summary: Teva Pharmaceuticals told a US federal judge that it has standing to bring monopolization claims accusing Corcept Therapeutics and Optime Care of blocking generic competition for Corcept’s branded drug...To view the full article, register now.
Already a subscriber? Click here to view full article